Mumbai-based Cipla is aiming to reach $1 billion in revenue from its United States business by fiscal year 2027, as the company continues to expand its product offerings and manufacturing footprint. The target comes amid rising global interest in generic and specialty medications, with Cipla positioning itself to tap into both.
The pharmaceutical firm, one of India's largest, currently generates around 28 percent of its total revenue from the North American market. In its latest earnings report for Q1 FY26, Cipla posted ₹12.98 billion (approx. $155 million) in net profit, up 10 percent year-on-year, and ₹69.57 billion (approx. $832 million) in revenue. North America contributed ₹19.33 billion (approx. $231 million), though this marked a 7 percent drop due to pricing pressure and increased competition.
Cipla plans to offset the anticipated decline in revenues from generic Revlimid, a cancer treatment facing patent expiration, by introducing several new drugs. These include generics of respiratory treatments like Symbicort and Advair, peptide therapies such as nano paclitaxel, and a series of biosimilars. The company also plans to grow its presence in respiratory care with expanded versions of its Synchrobreathe inhaler platform.
A key component of Cipla’s strategy is supply chain diversification. Its plant in China has already begun shipping inhalation products, and the company is currently in discussions to expand supply into two additional global markets. The facility is capable of producing up to 55 million units annually.
While analysts note that the US generics market remains highly competitive with ongoing pricing pressures, Cipla believes its upcoming launches and therapeutic diversity will help maintain momentum. Domestic performance in India remains strong, particularly in the areas of respiratory disease, diabetes, cardiology, and anti-infectives, offering additional financial stability as the company invests further in research and development.
India Ratings and Research recently reported that Indian drugmakers are likely to see continued US revenue growth in FY25, supported by persistent shortages and realignment in global pharmaceutical supply chains.